⌘K

Accelerating fibrosis and inflammation research through validated preclinical models and expert insights.

Research

Models
Drugs
Insights
Resources
Pathways

Company

Contact Us
Privacy Policy

© 2026 Fibrosis-Inflammation Lab. All rights reserved.

Insights & Research

Latest updates on fibrosis research, biomarkers, and drug development trends.

TAA-Induced Liver Fibrosis Model: Building Stable Cirrhosis and Biliary Lesions Beyond CCl4

An in-depth guide to the Thioacetamide (TAA) induced liver fibrosis model. Learn why its administration via drinking water, macronodular cirrhosis formation, and biliary involvement make it a superior choice to CCl4 for specific studies.

UUO (Unilateral Ureteral Obstruction) Renal Fibrosis Model: Complete Guide with Day 3/7/14 Timeline, Endpoints & Adenine Model Comparison

A comprehensive guide to the UUO renal fibrosis model covering the Day 3-21 fibrosis timeline, microsurgery optimization, Sirius Red/Hydroxyproline quantification endpoints, and strategic comparison with the adenine CKD model.

Complete Guide to the 5/6 Nephrectomy (Remnant Kidney) Model: Key Differences from the UUO Model

The 5/6 Nephrectomy model reproduces 'glomerular hyperfiltration and sclerosis,' the final common pathway of CKD progression. Learn the decisive differences from the short-term UUO model, surgical tips, and strategic model selection based on your drug target.

Comparing ALD and MASLD (NASH) Animal Models: How to Reproduce Alcoholic vs. Non-Alcoholic Features

Alcohol-associated Liver Disease (ALD) and Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). Though pathologically similar, the effective animal models and underlying mechanisms are completely different. A preclinical perspective on Lieber-DeCarli, NIAAA, and current MASH models.

Picrosirius Red Staining Protocol: Complete Guide to Sirius Red Collagen Quantification & Troubleshooting

Step-by-step Picrosirius Red staining protocol with ImageJ quantification, polarized light microscopy tips, and Masson's Trichrome comparison for fibrosis research.

MASH Preclinical Models FAQ: Selection Guide for GAN, CDA-HFD, & STAM™

Frequently asked questions about choosing the right MASH preclinical model (GAN Diet, CDA-HFD, STAM™). Learn how to avoid clinical failures by aligning animal models with your drug's Mechanism of Action (MoA).

In Vivo Imaging for Fibrosis Models: Longitudinal Assessment with MicroCT and Ultrasound

How MicroCT, high-frequency ultrasound, and MRI enable longitudinal fibrosis assessment in preclinical models. Covers HU thresholds, SWE, cardiac echo, study design, and 3Rs benefits.

ImageJ Fibrosis Quantification Guide: Stained Tissue Image Analysis Protocol

Step-by-step ImageJ (Fiji) protocol for quantifying fibrosis area fraction from Masson's trichrome, picrosirius red, and IHC/DAB-stained sections using Color Deconvolution and batch macros.

Hydroxyproline Assay: Principle, Protocol & Collagen Quantification (2026)

Hydroxyproline assay principle (Chloramine-T colorimetry) and 6-step protocol explained. Organ-specific tips for liver, lung & kidney, reference values, and kit comparison.

CCl4-Induced Liver Fibrosis Model: Protocols, Timelines, vs MASH Diet Models

A comprehensive guide on the carbon tetrachloride (CCl4) liver fibrosis model—the gold standard for pure anti-fibrotic drug screening. Learn protocols, typical staging (F1-F3), and when to choose this over MASH diet models.

Practical Guide to Renal Fibrosis Models: The Adenine-Induced CKD Model

A deep dive into the adenine-induced CKD model, the premier dietary/medical model for chronic kidney disease. We explore the mechanism of tubulointerstitial nephritis, its critical differences from the surgical UUO model, and tips for managing BUN/Creatinine evaluations.

M1 vs M2 Macrophage Polarization in Fibrosis: Mechanisms, Markers & Therapeutic Targets

M1 vs M2 macrophage polarization in fibrosis: surface markers, flow cytometry panel design, M2 subtypes (M2a/b/c), and drug targets including CSF1R and TREM2.